Table 3.
Exposure variable | Univariate analysis | Multivariable analysis | ||||
Unadjusted β coefficient (95% CI) | P values | R2 (%) | Adjusted β coefficient* (95% CI) | P values | R2 (%) | |
Depressive scores | −1.17 (−1.53 to 0.80) | <0.01 | 36.70 | −1.17 (−1.55 to 0.80) | <0.01 | 45.19 |
Adjusted for: | ||||||
Age | −0.20 (−0.77 to 0.37) | 0.48 | ||||
Sex (male vs female) | 7.02 (−1.18 to 15.22) | 0.09 | ||||
No of ARV medication (3 vs 2) | −4.49 (−12.32 to 3.33) | 0.26 | ||||
HIV staging | ||||||
Stages 2 vs 1 | −2.63 (−10.04 to 4.77) | 0.48 | ||||
Stages 3 vs 1 | −8.60 (−18.12 to 0.91) | 0.08 | ||||
Duration on ARV | ||||||
1–5 years vs <1 year | 7.83 (−6.63 to 22.29) | 0.28 | ||||
6–10 years vs <1 year | 9.29 (−5.16 to 23.73) | 0.20 | ||||
>10 years vs <1 year | 11.28 (−4.87 to 27.43) | 0.17 |
Bold, statistically significant results (p-values)
Notes: *Linear regression adjusted coefficient for quality of life.
ARV, antiretroviral.